Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “dabrafenib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 6
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 6 pipeline programs matching "dabrafenib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

6 results for “dabrafenib” Back to intelligence hub

Search results

  1. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial
  2. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial
  3. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial
  4. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial
  5. TRAME-13-25

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial
  6. dabrafenib

    Novartis Pharmaceuticals

    Melanoma

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.